A seemingly absurd causal chain just played out on Wall Street: A mild flu season torpedoed a healthcare giant’s earnings.
Abbott Laboratories (ABT) reported a 7.4% year-over-year drop in diagnostic sales, a decline management bluntly attributed to fewer people catching the flu this winter. The company slashed its full-year profit outlook, sending shares down more than 5% in response. For a “Dividend King” with a 54-year streak of payout hikes, blaming the weather is hardly the narrative investors want to hear. The pressing question: Is this a seasonal sniffle, or a symptom of deeper, chronic ailments?
Abbott runs on four engines: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals. This quarter, Medical Devices grew 8.5% and Pharma rose 6.6%. The only stall came from Diagnostics. The evaporation of respiratory testing demand single-handedly wiped 4.3 percentage points off the company’s operating margin.
In short, Abbott isn’t collapsing; it’s limping on one bad leg. The problem is that leg shows little sign of healing. Flu severity is uncontrollable, and the other pillar of the diagnostics unit—the flagship FreeStyle Libre 3 glucose monitor—is currently mired in its own regulatory and legal swamp.
Before Abbott can get back to sprinting, it must clear three significant hurdles.
With these three forces converging, it’s no mystery why the stock has essentially flatlined for the last five years.
But the bear case isn’t the only game in town. Abbott still holds two compelling cards close to the vest.
The first is Volt PFA. This pulsed field ablation system for treating atrial fibrillation (AFib) received FDA approval in December. With over 12 million Americans over 65 suffering from AFib—a number expected to double in two decades—Volt gives Abbott a premium entry ticket to the lucrative electrophysiology arena just as the market is heating up.
The second is that 54-year dividend track record. Even with a stagnant stock price over five years, total return (including reinvested dividends) has kept shareholders in positive territory. In a higher-for-longer interest rate environment, that kind of durable, growing income stream is a rare and valuable hedge.
If your clock ticks in months, Abbott’s near-term outlook is cloudy. The cyclical lull in flu season, lingering Libre 3 litigation, and the financial drag of integrating Exact Sciences will likely keep a lid on the stock.
But if your clock ticks in years, the calculus shifts. Cancer screening penetration is still in its infancy, the Volt PFA opportunity is just beginning, and a 54-year commitment to returning capital is the ultimate financial moat.
Abbott is stuck in a transition gear—the old engine (pandemic/flu testing) has sputtered out, and the new one (oncology screening/electrophysiology) hasn’t fully caught yet. For long-term investors willing to endure the noise, this could be a classic contrarian entry point. For those seeking a quick pop, this Dividend King might need a little more bed rest before it’s ready to run again.
